IGF-1R: a validated thyroid eye disease target and a re-emerging cancer target – a pipeline review

STUTTGART, Germany I September 05, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-IGF-1(R) immunotherapies in R&D: Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy.

This competitive intelligence report about IGF-1(R)-Targeted Immunotherapies provides an up-to-date competitor evaluation in the field of product candidates in research and development targeting IGF-1R or its ligand IGF-1. This report will be prepared on demand within one working day upon order placement. The report lists active IGF-1(R)-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of IGF-1(R)-targeted therapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

Insulin-like growth factor- receptor (IGF-1R) is a transmembrane tyrosine kinase receptor that plays a role in development, metabolism, and immune regulation, and is overexpressed in orbital fibroblasts (OFs), B, and T cells of thyroid ophthalmopathy in Graves’ disease. Blocking IGF-1(R) signalling reduces the expression of downstream inflammatory factors, thereby inhibiting the synthesis of hyaluronic acid and other glycosaminoglycans caused by OFs activation, as well as related inflammatory reactions including tissue congestion and edema; inhibit adipocyte cellularization of OFs, thereby reducing the disease activity of patients with active thyroid ophthalmopathy and improving proptosis, diplopia, ocular congestion and edema and other symptoms and signs. Clinical and commercial validation of IGF-1R as a target for treatment of thyroid eye disease (TED) is highlighted by 2024 global sales of nearly US$ 1.9 bln of the first approved anti-IGF-1R therapeutic antibody Tepezza.

IGF-1R has also emerged as a critical target in oncology due to its pivotal role in tumor growth, progression, and therapeutic resistance. IGF-1R was among the most intensively pursued kinase targets in oncology. However, even after a slew of small-molecule and antibody therapeutics reached clinical trials for a range of solid tumors, the initial promise remains unfulfilled. Mechanisms of resistance to, and toxicities resulting from, IGF-1R-targeted drugs are well-catalogued, and there is general appreciation of the fact that a lack of biomarker-based patient stratification was a limitation of previous clinical trials. But no next-generation therapeutic strategies have yet successfully exploited this understanding in the clinic.

Currently there is emerging interest in re-visiting IGF-1R targeted therapeutics in combination-treatment protocols with predictive biomarker-driven patient-stratification.

The report “Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-igf-1r-and-igf-1-targeted-immunotherapy/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation and the pre-scoped review of the pipeline of immunotherapies against customer-selected targets: Pipeline Review of Customer-Selected Targeted Immunotherapies: Pre-Scoped Competitor Analysis.

SOURCE: La Merie Publishing